WO2001085153A3 - Potentiation of antineoplastic agents using sigma-2 ligands - Google Patents

Potentiation of antineoplastic agents using sigma-2 ligands Download PDF

Info

Publication number
WO2001085153A3
WO2001085153A3 PCT/US2001/040688 US0140688W WO0185153A3 WO 2001085153 A3 WO2001085153 A3 WO 2001085153A3 US 0140688 W US0140688 W US 0140688W WO 0185153 A3 WO0185153 A3 WO 0185153A3
Authority
WO
WIPO (PCT)
Prior art keywords
sigma
antineoplastic agents
potentiation
ligands
cells
Prior art date
Application number
PCT/US2001/040688
Other languages
French (fr)
Other versions
WO2001085153A2 (en
Inventor
Keith W Crawford
Wayne D Bowen
Original Assignee
Us Gov Health & Human Serv
Keith W Crawford
Wayne D Bowen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Keith W Crawford, Wayne D Bowen filed Critical Us Gov Health & Human Serv
Priority to AU2001263502A priority Critical patent/AU2001263502A1/en
Priority to US10/275,830 priority patent/US20030171397A1/en
Publication of WO2001085153A2 publication Critical patent/WO2001085153A2/en
Publication of WO2001085153A3 publication Critical patent/WO2001085153A3/en
Priority to US11/497,945 priority patent/US20060270700A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the use of sigma-2 agonists to potentiate the activity of antineoplastic agents. These substances are useful for treating cancerous tumors and, in particular, drug resistant tumors in humans. Methods for sensitizing multidrug resistant cells to antitumor agents comprising contacting the cells with a sigma-2 agonist are also described.
PCT/US2001/040688 2000-05-11 2001-05-08 Potentiation of antineoplastic agents using sigma-2 ligands WO2001085153A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2001263502A AU2001263502A1 (en) 2000-05-11 2001-05-08 Potentiation of antineoplastic agents using sigma-2 ligands
US10/275,830 US20030171397A1 (en) 2001-05-08 2001-05-08 Potentiation of antineoplastic agents using sigma-2
US11/497,945 US20060270700A1 (en) 2000-05-11 2006-08-01 Potentiation of antineoplastic agents using sigma-2 ligands

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20322000P 2000-05-11 2000-05-11
US60/203,220 2000-05-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/497,945 Continuation US20060270700A1 (en) 2000-05-11 2006-08-01 Potentiation of antineoplastic agents using sigma-2 ligands

Publications (2)

Publication Number Publication Date
WO2001085153A2 WO2001085153A2 (en) 2001-11-15
WO2001085153A3 true WO2001085153A3 (en) 2002-08-15

Family

ID=22753022

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/040688 WO2001085153A2 (en) 2000-05-11 2001-05-08 Potentiation of antineoplastic agents using sigma-2 ligands

Country Status (2)

Country Link
AU (1) AU2001263502A1 (en)
WO (1) WO2001085153A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130171A1 (en) * 2001-10-30 2003-07-10 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant microbial cells
WO2004064775A2 (en) * 2003-01-16 2004-08-05 The United States Of America As Represented By The Secretary Department Of Health And Human Services Sigma-2 receptor agonists and their use in the treatment of hiv infection
FR2970869B1 (en) * 2011-01-31 2013-09-06 Centre Nat Rech Scient USE OF THE SIGMA-1 RECEPTOR FOR REGULATING THE EXPRESSION OF IONIC CHANNELS AT THE POST-TRANSCRIPTIONAL LEVEL
JP2023526515A (en) 2020-05-20 2023-06-21 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ Methods for treating lysosomal storage diseases with histatin peptides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH681780A5 (en) * 1991-02-25 1993-05-28 Patrinove Anticancer compsns. - consists of a cytotoxic agent with a agent to prevent multi:drug resistance, e.g. in liposome(s)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH681780A5 (en) * 1991-02-25 1993-05-28 Patrinove Anticancer compsns. - consists of a cytotoxic agent with a agent to prevent multi:drug resistance, e.g. in liposome(s)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOWEN W D ET AL: "Sigma receptor ligands modulate expression of the multidrug resistance gene in human and rodent brain tumor cell lines (Meeting abstract).", PROC ANNU MEET AM ASSOC CANCER RES, (1997). VOL. 38, PP. A3206. ISSN: 0197-016X., Unit on Receptor Biochemistry and Pharmacology, Laboratory of Medicinal Chemistry, NIDDK, NIH, Bethesda, MD 20892., XP001036622 *
HOFSLI, EVA ET AL: "Reversal of multidrug resistance by lipophilic drugs", CANCER RES. (1990), 50(13), 3997-4002, XP002056218 *
KEARSLEY J H ET AL: "Single-agent versus combination antiemetic treatments in patients receiving cytotoxic chemotherapy.", MEDICAL JOURNAL OF AUSTRALIA, (1982). VOL. 2, NO. 1, PP. 32-4. JOURNAL CODE: M26. ISSN: 0025-729X., XP001036597 *
LASZLO J.: "Nausea and vomiting as major complications of cancer chemotherapy.", DRUGS, (1983) 25/SUPPL. 1 (1-7). CODEN: DRUGAY, XP001036592 *
NEIDHART J A ET AL: "Comparative trial of the antiemetic effects of THC and haloperidol--.", JOURNAL OF CLINICAL PHARMACOLOGY, (1981). 21 (8-9 SUPPL.), PP. 38S-42S. JOURNAL CODE: HT9. ISSN: 0091-2700., XP001036720 *

Also Published As

Publication number Publication date
AU2001263502A1 (en) 2001-11-20
WO2001085153A2 (en) 2001-11-15

Similar Documents

Publication Publication Date Title
WO2006065392A3 (en) Cancer treatments
AR033555A1 (en) PRODUCT FOR THE TREATMENT OF POSITIVE STROGEN RECEIVER CARCINOMA, AND USE OF THIS PRODUCT TO PREPARE MEDICINES
BRPI0612845A8 (en) compound, pharmaceutical formulation, methods for treating cancer and for synthesizing a compound of formula
BR0207378A (en) Cancer treatment
WO2004081190A3 (en) Uses of il-23 agonists and antagonists; related reagents
EA200501586A1 (en) PHARMACEUTICAL PRODUCTS
NO20052285D0 (en) Solid particulate antifungal preparations for pharmaceutical use
WO2007100727A3 (en) Nanosecond pulsed electric fields cause melanomas to self-destruct
HK1080447A1 (en) Retinol derivatives, their use in the treatment ofcancer and for potentiating the efficacy of other cytotoxic agents
WO2005000211A3 (en) Method for treating diseases using hsp90-inhibiting agents in combination with platinum coordination complexes
DE60004348D1 (en) COMBINED PREPARATIONS THAT MORPHOLIN ANTHRACYCLIN AND PLATIN DERIVATIVES
IS5662A (en) Thienylazolylalkoxyethanamines, their preparation and use as drugs
ZA200205191B (en) LIV-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer.
NO20043565L (en) Heteroberl-substituted 2-pyridinyl and 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido [1,2-a] pyrimidin-4-one derivatives.
EE03858B1 (en) Conjugates, their use in prostate cancer drugs, pharmaceutical composition and its preparation
WO2004058153A9 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
WO2004098524A3 (en) Lipid platinum complexes and methods of use thereof
WO2001062235A3 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
BR0010709B1 (en) use of lh for the production of a drug to induce paucifoliculogenesis or unifoliculogenesis in anovulatory women.
PL369148A1 (en) Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
WO2005011590A3 (en) Compositions and methods for restoring sensitivity to treatment with her2 antagonists
WO2001085153A3 (en) Potentiation of antineoplastic agents using sigma-2 ligands
MY136822A (en) Derivatives of [6, 7-dihydro-5h-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide and their use as inhibitors upon the interaction of cams and leukointegrins
AU2003215381A1 (en) EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER
AU2003297775A1 (en) Leach resistant oil based carrier for cosmetically and pharmaceutically active agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10275830

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP